Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) FCF Margin (2016 - 2023)

Historic FCF Margin for Spyre Therapeutics (SYRE) over the last 7 years, with Q2 2023 value amounting to 2419.04%.

  • Spyre Therapeutics' FCF Margin rose 8886400.0% to 2419.04% in Q2 2023 from the same period last year, while for Mar 2024 it was 15806.83%, marking a year-over-year decrease of 96681200.0%. This contributed to the annual value of 11276.52% for FY2023, which is 78337600.0% down from last year.
  • Latest data reveals that Spyre Therapeutics reported FCF Margin of 2419.04% as of Q2 2023, which was up 8886400.0% from 8906.06% recorded in Q1 2023.
  • Over the past 5 years, Spyre Therapeutics' FCF Margin peaked at 17.1% during Q2 2021, and registered a low of 10797.62% during Q4 2022.
  • Its 3-year average for FCF Margin is 4075.09%, with a median of 2419.04% in 2023.
  • Its FCF Margin has fluctuated over the past 5 years, first crashed by -102688600bps in 2022, then soared by 8886400bps in 2023.
  • Quarter analysis of 3 years shows Spyre Therapeutics' FCF Margin stood at 528.76% in 2021, then crashed by -1942bps to 10797.62% in 2022, then skyrocketed by 78bps to 2419.04% in 2023.
  • Its last three reported values are 2419.04% in Q2 2023, 8906.06% for Q1 2023, and 10797.62% during Q4 2022.